Zika Virus Testing Market Overview
The Zika Virus Testing Market is expanding as healthcare systems strengthen surveillance for mosquito-borne diseases, improve outbreak preparedness, and adopt faster molecular diagnostic technologies. Climate-driven expansion of Aedes mosquito habitats, increasing investment in vector-borne disease surveillance, and the growing use of multiplex molecular platforms are supporting demand for accurate and timely Zika virus testing.
According to the Market Research Future report updated August 24, 2026, the global Zika Virus Testing Market was valued at USD 255.50 million in 2025 and is projected to grow from USD 273.50 million in 2026 to USD 482.00 million by 2035, registering a CAGR of 6.50% during the forecast period 2025–2035. North America held the largest share with 38.5% of global revenue in 2025, while Asia-Pacific is projected to be the fastest-growing region at a 7.60% CAGR through 2035. Molecular tests accounted for 62.5% of 2025 market revenue, while point-of-care molecular assays are projected to record the fastest growth at a 9.10% CAGR.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
Key players driving innovation and competitiveness in the Zika Virus Testing Market include:
Hologic, Inc.
Abbott Laboratories
Roche Diagnostics
Quest Diagnostics
Bio-Rad Laboratories
bioMérieux SA
Siemens Healthineers
Chembio Diagnostics
Euroimmun (Revvity)
InBios International
The market is being shaped by the transition toward molecular and multiplex diagnostic platforms that can differentiate Zika from other arboviruses such as dengue and chikungunya. Sample-to-answer molecular systems are helping laboratories reduce testing turnaround times, while AI-assisted assay design is being explored to address cross-reactivity challenges associated with conventional serological testing. Decentralized molecular testing is also gaining importance as healthcare providers and public-health agencies seek diagnostic solutions that can operate closer to patients and in resource-constrained environments.
The Zika Virus Testing Market can be segmented by Test Type, Sample Type, End User, and Region. By test type, the market includes Molecular Tests, Serologic Tests, and Plaque Reduction Neutralization Test (PRNT), with Molecular Tests holding the dominant share and Point-of-Care Molecular Assays representing the fastest-growing testing format. By sample type, Blood and Serum dominate with a 76.0% share in 2025, while Saliva and other non-invasive sample protocols are projected to grow at an 8.55% CAGR. By end user, Hospitals and Clinics account for the largest share at 51.5%, while Point-of-Care Settings and Home Testing are projected to expand at a 7.95% CAGR. Regional markets include North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.
Significant opportunities are emerging from CRISPR-based diagnostics, isothermal amplification, saliva-based self-collection, connected molecular analyzers, and laboratory upgrades across emerging markets. Expansion of regional molecular diagnostic infrastructure in Asia-Pacific and other tropical regions can create new opportunities for manufacturers offering ambient-stable reagents, portable testing platforms, and integrated arboviral surveillance solutions.
Recent Developments and Market Trends:
The growing adoption of multiplex molecular platforms is enabling laboratories to simultaneously differentiate Zika, dengue, chikungunya, and other arboviral infections from a single patient sample.
Point-of-care molecular testing is gaining momentum as healthcare providers seek faster diagnostic results for emergency departments, maternal health programs, travel medicine, and outbreak response.
Saliva-based testing and other non-invasive sample collection methods are attracting attention because they can simplify specimen collection and improve testing accessibility.
AI-assisted assay development is emerging as a technology trend aimed at improving primer and probe specificity and reducing cross-reactivity among closely related flaviviruses.
Connected diagnostic platforms and decentralized testing are supporting real-time surveillance by enabling molecular test results to be transmitted from remote and resource-constrained settings to public-health networks.
Reasons to Buy the Report:
Understand the projected growth trajectory of the Zika Virus Testing Market through 2035, including its 6.50% CAGR and forecast valuation of USD 482.00 million.
Assess the competitive landscape and strategic positioning of leading molecular, serological, and point-of-care diagnostic companies.
Identify the fastest-growing test type, sample type, end-user, and regional segments shaping future market opportunities.
Evaluate major market drivers, restraints, technological developments, and emerging opportunities influencing Zika diagnostic adoption.
Gain strategic insights into multiplex molecular testing, decentralized diagnostics, CRISPR-based technologies, saliva collection, and emerging-market laboratory infrastructure.
Future Outlook:
The Zika Virus Testing Market is expected to experience sustained growth through 2035 as governments, diagnostic laboratories, hospitals, and public-health organizations strengthen arboviral surveillance and preparedness. Molecular Tests are expected to remain the dominant test type because of their role in confirming active infection, while point-of-care molecular assays are projected to be the fastest-growing testing format. Blood and serum will continue to account for the largest share of sample types because of established laboratory workflows, while saliva-based protocols are expected to expand rapidly due to their non-invasive collection advantages. Hospitals and Clinics are expected to remain the leading end-user segment, although point-of-care settings and home testing are positioned for strong growth. North America is expected to maintain regional leadership, supported by established diagnostic infrastructure and regulatory readiness, while Asia-Pacific is projected to remain the fastest-growing regional market as countries expand laboratory networks and outbreak preparedness. Overall, advances in multiplex diagnostics, AI-assisted assay development, decentralized testing, climate-adaptation surveillance, and emerging molecular technologies are expected to support the market’s expansion to USD 482.00 million by 2035.
➤➤Explore Our Latest Related Reports:
